Alamar Biosciences (ALMR) investor relations material

Executive summary

• Achieved Q2 2026 revenue of $29.4 million, up 82% year-over-year, driven by strong growth in consumables, instruments, and new product launches, including multiplexed blood-based immunoassays and the Neuro 220 Panel.

• Completed a successful IPO in April 2026, raising $197.8 million in net proceeds and converting $56.5 million in convertible notes to equity.

• Expanded global partnerships, notably with Gates Ventures and the Alzheimer's Disease Data Initiative, targeting over 140,000 samples by 2027.

• Cumulative publications and preprints reached 165, highlighting broad platform impact, especially in neurodegeneration.

• Provided full-year 2026 revenue guidance of $116–$120 million, representing 59% growth at midpoint over 2025.

Financial highlights

• Q2 2026 revenue was $29.4 million, up from $16.2 million in Q2 2025; six-month revenue totaled $55.5 million (+90% YoY).

• Consumables revenue grew 147% year-over-year to $15.5 million, representing 53% of total revenue; instrument revenue reached $7.8 million, up 35% year-over-year.

• Gross profit was $17.7 million with a 60% gross margin, up from 53% last year.

• Operating expenses rose to $31.3 million, reflecting investments in R&D and SG&A.

• Net loss was $13.2 million, compared to $7.0 million in Q2 2025.

• Ended Q2 with $256.3 million in cash, equivalents, and investments.

Outlook and guidance

• Full-year 2026 revenue expected between $116 million and $120 million, representing 59% annual growth at midpoint.

• Plans to grow installed base by at least 100 instruments, targeting over 200 total placements and maintaining per instrument pull-through above $400,000.

• Management anticipates sustained momentum from recent product launches and expanded partnerships.

• Continued investment in commercial and R&D headcount, with focus on disciplined path to profitability.

• Submission of ARGO HT/DX for FDA approval planned for 2027.